10 withdrawn. 10 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Withdrawn 10 |
| Phase 2 | 4 | Withdrawn 4 |
Follow Primary Myelofibrosis: new trials by email Literature Review of Primary Myelofibrosis trials Research Report on Primary Myelofibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Captopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis/Myeloproliferative Neoplasms Captopril - Bone Marrow Fibrosis, Myeloproliferative Neoplasm | Phase 1 / Phase 2 | Withdrawn | Case Comprehensive Cancer Center | 2024-04-01 | 2023-10-11 | |
| A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia LNK01002 - Acute Myeloid Leukemia, Primary Myelofibrosis | Phase 1 | Withdrawn | Lynk Pharmaceuticals Co., Ltd | 2021-04-08 | 2023-06-18 | |
| A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy APG-1252, Ruxolitinib - Myelofibrosis | Phase 1 / Phase 2 | Withdrawn | Ascentage Pharma Group Inc. | 2020-12-15 | 2022-07-12 | |
| Study of Select Combinations in Adults With Myelofibrosis MBG453, NIS793, Spartalizumab - Primary Myelofibrosis, Myelofibrosis | Phase 1 | Withdrawn | Novartis Pharmaceuticals | 2020-11-30 | 2021-03-04 | |
| HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation MDG1021 dose 1, MDG1021 dose 2, MDG1021 dose 3 - Acute Myeloid Leukemia, Acute Lymphoid Leukemia | Phase 1 | Withdrawn | Medigene AG | 2020-07-02 | 2021-10-08 | |
| Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) Pacritinib, Decitabine - Chronic Myelomonocytic Leukemia, Juvenile Myelomonocytic Leukemia | Phase 1 | Withdrawn | Washington University School of Medicine | 2017-06-01 | 2017-05-08 | |
| Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis Durvalumab, Laboratory Biomarker Analysis - Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis | Phase 1 | Withdrawn | Northwestern University | 2016-11-01 | 2019-08-20 | |
| Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Fludarabine Phosphate - Acute Myeloid Leukemia in Remission, Primary Myelofibrosis | Phase 1 | Withdrawn | City of Hope Medical Center | 2015-11-01 | 2016-09-14 | |
| Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer cyclosporine, mycophenolate mofetil, pentostatin - Chronic Myeloproliferative Disorders, Leukemia | Phase 1 / Phase 2 | Withdrawn | University of Nebraska | 2008-09-01 | 2023-08-14 | |
| Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies Edetate Calcium Disodium, Ethanol, Trimethoprim-sulfamethoxazole - Chronic Myeloproliferative Disorders, Infection | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2013-02-15 |
Myeloproliferative Disorders (6) · Polycythemia Vera (6) · Leukemia, Myeloid, Acute (4) · Myelodysplastic Syndromes (4) · Leukemia, Myelomonocytic, Chronic (3) · Lymphoma (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Thrombocythemia, Essential (3) · Blast Crisis (2) · Congenital Abnormalities (2) · Leukemia (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Myeloid, Accelerated Phase (2) · Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (2)
Bone Marrow Diseases (10) · Hematologic Diseases (10) · Hemic and Lymphatic Diseases (10) · Neoplasms (7) · Neoplasms by Site (7) · Bone Marrow Neoplasms (6) · Hematologic Neoplasms (6) · Leukemia, Myeloid (5) · Neoplasms by Histologic Type (5) · Blood Platelet Disorders (4) · Chronic Disease (4) · Disease Attributes (4) · Hemorrhagic Disorders (4) · Myeloproliferative Disorders (4) · Pathologic Processes (4)
Decitabine (2) · Peripheral Blood Stem Cell Transplantation (2) · ruxolitinib (2) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (1) · Captopril (1) · Cyclosporine (1) · Cyclosporins (1) · Cytogenetic Analysis (1) · Disulfides (1) · Edetic Acid (1) · Ethanol (1) · Flow Cytometry (1) · Immunoenzyme Techniques (1) · Immunoglobulin G (1) · In Situ Hybridization, Fluorescence (1)
Ascentage Pharma Group Inc. (1) · Case Comprehensive Cancer Center (1) · City of Hope Medical Center (1) · Lynk Pharmaceuticals Co., Ltd (1) · M.D. Anderson Cancer Center (1) · Medigene AG (1) · Northwestern University (1) · Novartis Pharmaceuticals (1) · University of Nebraska (1) · Washington University School of Medicine (1)
United States (5) · Netherlands (1)
Aaron Gerds, MD (1) · Brady Stein, MD, MHS (1) · Camille Abboud, M.D. (1) · Haris Ali (1) · Jorge Cortes, MD (1) · Linda Wei, M.D. (1) · Patrick Chaftari, MD (1) · Peter van Balen, MD (1) · Rene Goedkoop, MD (1) · Robert Bociek, MD (1) · Yifan Zhai, MD, PhD (1)
2019 (1), P30CA036727 (1), P30CA060553 (1)